peoplePerson
Christof von Kalle
Gene therapy pioneer who developed methods to track vector integration in treated patients.
Christof von Kalle developed integration-site analysis that revealed insertional mutagenesis in early gene therapy trials, and led translational oncology at NCT Heidelberg before moving to Berlin.
Role
Director, Clinical Study Center, Berlin Institute of Health at Charité
Institution
Specialisms
Gene therapyCell therapy safetyTranslational research
Profiles
Pages like this
not linked directly; found by shared links- PersonBruce L. Levine
Shares In vivo CAR-T, CAR-T cell therapy.
- IdeaHospital-exemption cell therapies at scale, backed by a shared registry
Shares Charité – Universitätsmedizin Berlin, CAR-T cell therapy.
- IdeaIn vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma
Shares In vivo CAR-T, CAR-T cell therapy.
- IdeaIn vivo CAR-T against solid-tumour antigens
Shares In vivo CAR-T, CAR-T cell therapy.
- TechnologyLogic-gated therapeutics (AND, NOT gates)
Shares In vivo CAR-T, CAR-T cell therapy.
- IdeaIn vivo CAR-T manufactured and priced like a generic biologic
Shares In vivo CAR-T, CAR-T cell therapy.
- TermLymphodepletion before CAR-T
Shares In vivo CAR-T, CAR-T cell therapy.
- Key paperUCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL
Shares In vivo CAR-T, CAR-T cell therapy.